Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease.

BACKGROUND Although chronic obstructive pulmonary disease (COPD) has been considered a disease of Caucasian men, recent data show mortality rising faster among women and African-Americans. Some have suggested these groups are more susceptible to tobacco smoke. We examined this issue in our own population of COPD patients. METHODS Beginning in March 2003 we prospectively developed a COPD research database to facilitate recruitment for clinical trials. Enrollees are recruited from clinics and paid advertising and their demographics, medical/smoking histories, and spirometric data are recorded. We examined the smoking histories and pulmonary function of enrollees over 45, with 20 pack-years of smoking, FEV(1)/FVC (forced expiratory volume forced vital capacity) <0.70, and a race-adjusted post-bronchodilator FEV(1)<80%. The primary outcome was the loss of lung function per pack-year smoked, or Susceptibility Index (SI), calculated using the formula: (% predicted FEV(1)-100)/pack-years. RESULTS A total of 585 patients enrolled during the study period and 330 met our inclusion criteria. Caucasians were older than African-Americans (63 vs. 58, P=0.0003) and had more pack-years of smoking (57 vs. 43, P=0.0003). There were no differences in lung function or bronchodilator reversibility among the racial or gender subgroups. Caucasians had less loss of lung function per pack-year smoked than African-Americans (SI=-1.02% vs. -1.34%, P=0.007) and men less than women (SI=-0.98% vs. -1.21%, P=0.001). Caucasian males appeared relatively protected from tobacco smoke (SI=-0.93%), while African-American women appeared most susceptible (SI=-1.42%). CONCLUSIONS There are important differences in racial and gender susceptibility to tobacco smoke among patients with COPD. African-American females appear to be at highest risk and may benefit most from smoking cessation.

[1]  J. Donohue.  Therapeutic responses in asthma and COPD. Bronchodilators. , 2004, Chest.

[2]  Dirkje S Postma,et al.  Rationale for the Dutch hypothesis. Allergy and airway hyperresponsiveness as genetic factors and their interaction with environment in the development of asthma and COPD. , 2004, Chest.

[3]  K. Sekizawa,et al.  CLCA1 gene polymorphisms in chronic obstructive pulmonary disease , 2004, Journal of Medical Genetics.

[4]  G. Criner,et al.  Smoking patterns in African Americans and whites with advanced COPD. , 2004, Chest.

[5]  J. Donohue,et al.  A Short-Term Comparison of Fluticasone Propionate/Salmeterol with Ipratropium Bromide/Albuterol for the Treatment of COPD , 2004, Treatments in respiratory medicine.

[6]  S. Spencer,et al.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.

[7]  F. Serres.  Worldwide Racial and Ethnic Distribution of α1-Antitrypsin Deficiency: Summary of an Analysis of Published Genetic Epidemiologic Surveys , 2002 .

[8]  D. Mannino,et al.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[9]  D. Jacobs,et al.  Early life factors contribute to the decrease in lung function between ages 18 and 40: the Coronary Artery Risk Development in Young Adults study. , 2002, American journal of respiratory and critical care medicine.

[10]  D. Tashkin,et al.  Gender bias in the diagnosis of COPD. , 2001, Chest.

[11]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[12]  A. Evans,et al.  Trends in cigarette smoking in 36 populations from the early 1980s to the mid-1990s: findings from the WHO MONICA Project. , 2001, American journal of public health.

[13]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[14]  D. Hansell,et al.  Effect of lung-volume-reduction surgery in patients with severe emphysema. , 2000, The New England journal of medicine.

[15]  C. C. Johnson,et al.  Racial differences in physiologic parameters related to asthma among middle-class children. , 2000, Chest.

[16]  F. Speizer,et al.  Race and gender differences in the effects of smoking on lung function. , 2000, Chest.

[17]  P. Barnes.  Molecular genetics of chronic obstructive pulmonary disease , 1999 .

[18]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[19]  B. McCarthy,et al.  Health service use by African Americans and Caucasians with asthma in a managed care setting. , 1998, American journal of respiratory and critical care medicine.

[20]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[21]  D. Shopland.  Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. , 1995, Environmental health perspectives.

[22]  A. Buist,et al.  Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. , 1994, American journal of respiratory and critical care medicine.

[23]  D. Dockery,et al.  Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. , 1992, The American review of respiratory disease.

[24]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[25]  S. Horne,et al.  Increased susceptibility to lung dysfunction in female smokers. , 1991, The American review of respiratory disease.

[26]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.